ALX148

Phase 2Small molecule

QQuantumLeap Healthcare Collaborative

ALX148 is one of 64 small molecule programs targeting HER2-positive Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HER2-Positive Breast CancerRecruiting

Ovarian CancerActive, not recruiting

HER2-Positive Breast CancerPreclinical

Recruiting

Ovarian CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

232 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

88 2

Gemzar

Johnson & Johnson

Phase 3

33 3

Hycamtin

MMeitheal

Phase 3

26 4

Pegylated Liposomal Doxorubicin

Merck & Co.

Phase 3

35 5

Femara

Novartis

Phase 3

8 6

Imfinzi

AstraZeneca

Phase 3

8 7

Opdivo

Bristol-Myers Squibb

Phase 3

8 8

Adriamycin

Pfizer

Phase 3

8 9

Lynparza

RRisen (Suzhou) Pharma Tech Co., Ltd.

Zepzelca

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Active, not recruiting

Ovarian Cancer

NCT05467670

Q4 2031

PreclinicalRecruiting

HER2-Positive Breast Cancer

NCT05868226

Clinical

Trials by Indication[1]

HER2-positive Breast Cancer1 trial

PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/II Platform Trial

Recruiting·QQuantumLeap Healthcare Collaborative·Preclinical·NCT05868226·280 enrolled

Ovarian Cancer1 trial

Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Patients With Recurrent Platinum-resistant Ovarian Cancer: Phase II Study

Active, not recruiting·AAlexander B Olawaiye, MD·Phase 2·NCT05467670·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ALX148. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALX148 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALX148. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — QuantumLeap Healthcare Collaborative company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: QQuantumLeap Healthcare Collaborative

ALX148

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Q4 2031

Trials by Indication[1]

HER2-positive Breast Cancer1 trial

Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News